Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort
Renal dysfunction is a key risk factor for all-cause mortality in patients with type 2 diabetes (T2D). Circulating tumor necrosis factor receptor 1 (TNFR1) was recently suggested as a strong biomarker for end-stage renal failure in T2D. However, its relevance regarding all-cause death has yet to be...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2014-05, Vol.37 (5), p.1425-1431 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1431 |
|---|---|
| container_issue | 5 |
| container_start_page | 1425 |
| container_title | Diabetes care |
| container_volume | 37 |
| creator | SAULNIER, Pierre-Jean GAND, Elise VELHO, Gilberto SOSNER, Philippe ZAOUI, Philippe HADJADJ, Samy RAGOT, Stephanie DUCROCQ, Gregory HALIMI, Jean-Michel HULIN-DELMOTTE, Charlotte LLATY, Pierre MONTAIGNE, David RIGALLEAU, Vincent ROUSSEL, Ronan |
| description | Renal dysfunction is a key risk factor for all-cause mortality in patients with type 2 diabetes (T2D). Circulating tumor necrosis factor receptor 1 (TNFR1) was recently suggested as a strong biomarker for end-stage renal failure in T2D. However, its relevance regarding all-cause death has yet to be conclusively established. We aimed to assess the prognostic value of serum TNFR1 concentration for all-cause death in T2D and diabetic kidney disease (DKD) from the SURDIAGENE (Survie, Diabete de type 2 et Genetique) study.
A total of 522 T2D patients with DKD (estimated glomerular filtration rate [eGFR] 30 mg/mmol) were followed for a median duration of 48 months, and 196 deaths occurred.
Incidence rate (95% CI) for death increased as quartiles of TNFR1 concentration increased (first quartile: 4.7% patient-years [3.0-6.3%]; second quartile: 7.7% [5.4-10.0%]; third quartile: 9.3% [6.7-11.9%]; fourth quartile: 15.9% [12.2-19.5%]). In multivariate analysis taking age, diabetes duration, HbA1c, uACR, and eGFR into account, compared with the first quartile, patients from the fourth quartile had an adjusted hazard ratio for death of 2.98 (95% CI 1.70-5.23). The integrated discrimination improvement index was statistically significant when adding TNFR1 concentration to the UK Prospective Diabetes Study outcome equation (P = 0.031).
TNFR1 is a strong prognostic factor for all-cause mortality in T2D with renal dysfunction, and its clinical utility is suggested in addition to established risk factors for all-cause mortality. |
| doi_str_mv | 10.2337/dc13-2580 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1518814178</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1518814178</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-e18720ddf94d1287b1ce0aa2daf527730dfa69cd8c8769a03d1e4a88af71e4763</originalsourceid><addsrcrecordid>eNpd0c1qGzEQB3BRGho37aEvUASl0B621deutLmZjZ2EpGlJHHpcxpIWK6wlV9ol-H3yoJWxk0JPEpqfZgb-CH2g5BvjXH43mvKClYq8QhNa87IoS6Feowmhoi7KumbH6G1KD4QQIZR6g46ZqBgnrJqgp2lKQTsYXPA4dPjOxnGNm-C19UN8eV7czG8p_u2GFZ72fdHAmCz-EeIAvRu22Hn8K9v8Je3RYruxmOEzB0s72ITBG9ysYvBO4ytnvN3mWrKQ7Cmeh74Pj8W42Q0aVhbf3d-eXU7PZzezvMgqD3mHjjrok31_OE_Q_Xy2aC6K65_nl830utBcqqGwVElGjOlqYShTckm1JQDMQFcyKTkxHVS1NkorWdVAuKFWgFLQyXyRFT9BX_Z9NzH8GW0a2rVL2vY9eBvG1NKSKkUFlSrTT__RhzBGn7fLilHKRCnrrL7ulY4hpWi7dhPdGuK2paTdRdfuomt30WX78dBxXK6teZHPWWXw-QAgaei7CF679M8pIaqaS_4XoLmfig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1521124579</pqid></control><display><type>article</type><title>Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>SAULNIER, Pierre-Jean ; GAND, Elise ; VELHO, Gilberto ; SOSNER, Philippe ; ZAOUI, Philippe ; HADJADJ, Samy ; RAGOT, Stephanie ; DUCROCQ, Gregory ; HALIMI, Jean-Michel ; HULIN-DELMOTTE, Charlotte ; LLATY, Pierre ; MONTAIGNE, David ; RIGALLEAU, Vincent ; ROUSSEL, Ronan</creator><creatorcontrib>SAULNIER, Pierre-Jean ; GAND, Elise ; VELHO, Gilberto ; SOSNER, Philippe ; ZAOUI, Philippe ; HADJADJ, Samy ; RAGOT, Stephanie ; DUCROCQ, Gregory ; HALIMI, Jean-Michel ; HULIN-DELMOTTE, Charlotte ; LLATY, Pierre ; MONTAIGNE, David ; RIGALLEAU, Vincent ; ROUSSEL, Ronan ; SURDIAGENE Study Group ; for the SURDIAGENE Study Group</creatorcontrib><description>Renal dysfunction is a key risk factor for all-cause mortality in patients with type 2 diabetes (T2D). Circulating tumor necrosis factor receptor 1 (TNFR1) was recently suggested as a strong biomarker for end-stage renal failure in T2D. However, its relevance regarding all-cause death has yet to be conclusively established. We aimed to assess the prognostic value of serum TNFR1 concentration for all-cause death in T2D and diabetic kidney disease (DKD) from the SURDIAGENE (Survie, Diabete de type 2 et Genetique) study.
A total of 522 T2D patients with DKD (estimated glomerular filtration rate [eGFR] <60 and/or urinary albumin-to-creatinine ratio [uACR] >30 mg/mmol) were followed for a median duration of 48 months, and 196 deaths occurred.
Incidence rate (95% CI) for death increased as quartiles of TNFR1 concentration increased (first quartile: 4.7% patient-years [3.0-6.3%]; second quartile: 7.7% [5.4-10.0%]; third quartile: 9.3% [6.7-11.9%]; fourth quartile: 15.9% [12.2-19.5%]). In multivariate analysis taking age, diabetes duration, HbA1c, uACR, and eGFR into account, compared with the first quartile, patients from the fourth quartile had an adjusted hazard ratio for death of 2.98 (95% CI 1.70-5.23). The integrated discrimination improvement index was statistically significant when adding TNFR1 concentration to the UK Prospective Diabetes Study outcome equation (P = 0.031).
TNFR1 is a strong prognostic factor for all-cause mortality in T2D with renal dysfunction, and its clinical utility is suggested in addition to established risk factors for all-cause mortality.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc13-2580</identifier><identifier>PMID: 24623026</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Biomarkers ; Biomarkers - blood ; Cause of Death ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - mortality ; Diabetes. Impaired glucose tolerance ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - mortality ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Epidemiology ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Follow-Up Studies ; General aspects ; Glomerular Filtration Rate - physiology ; Humans ; Kidney diseases ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - etiology ; Kidney Failure, Chronic - mortality ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Mortality ; Prognosis ; Prospective Studies ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Receptors, Tumor Necrosis Factor, Type I - blood ; Risk Factors ; TNF inhibitors</subject><ispartof>Diabetes care, 2014-05, Vol.37 (5), p.1425-1431</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright American Diabetes Association May 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-e18720ddf94d1287b1ce0aa2daf527730dfa69cd8c8769a03d1e4a88af71e4763</citedby><cites>FETCH-LOGICAL-c378t-e18720ddf94d1287b1ce0aa2daf527730dfa69cd8c8769a03d1e4a88af71e4763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28446937$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24623026$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SAULNIER, Pierre-Jean</creatorcontrib><creatorcontrib>GAND, Elise</creatorcontrib><creatorcontrib>VELHO, Gilberto</creatorcontrib><creatorcontrib>SOSNER, Philippe</creatorcontrib><creatorcontrib>ZAOUI, Philippe</creatorcontrib><creatorcontrib>HADJADJ, Samy</creatorcontrib><creatorcontrib>RAGOT, Stephanie</creatorcontrib><creatorcontrib>DUCROCQ, Gregory</creatorcontrib><creatorcontrib>HALIMI, Jean-Michel</creatorcontrib><creatorcontrib>HULIN-DELMOTTE, Charlotte</creatorcontrib><creatorcontrib>LLATY, Pierre</creatorcontrib><creatorcontrib>MONTAIGNE, David</creatorcontrib><creatorcontrib>RIGALLEAU, Vincent</creatorcontrib><creatorcontrib>ROUSSEL, Ronan</creatorcontrib><creatorcontrib>SURDIAGENE Study Group</creatorcontrib><creatorcontrib>for the SURDIAGENE Study Group</creatorcontrib><title>Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>Renal dysfunction is a key risk factor for all-cause mortality in patients with type 2 diabetes (T2D). Circulating tumor necrosis factor receptor 1 (TNFR1) was recently suggested as a strong biomarker for end-stage renal failure in T2D. However, its relevance regarding all-cause death has yet to be conclusively established. We aimed to assess the prognostic value of serum TNFR1 concentration for all-cause death in T2D and diabetic kidney disease (DKD) from the SURDIAGENE (Survie, Diabete de type 2 et Genetique) study.
A total of 522 T2D patients with DKD (estimated glomerular filtration rate [eGFR] <60 and/or urinary albumin-to-creatinine ratio [uACR] >30 mg/mmol) were followed for a median duration of 48 months, and 196 deaths occurred.
Incidence rate (95% CI) for death increased as quartiles of TNFR1 concentration increased (first quartile: 4.7% patient-years [3.0-6.3%]; second quartile: 7.7% [5.4-10.0%]; third quartile: 9.3% [6.7-11.9%]; fourth quartile: 15.9% [12.2-19.5%]). In multivariate analysis taking age, diabetes duration, HbA1c, uACR, and eGFR into account, compared with the first quartile, patients from the fourth quartile had an adjusted hazard ratio for death of 2.98 (95% CI 1.70-5.23). The integrated discrimination improvement index was statistically significant when adding TNFR1 concentration to the UK Prospective Diabetes Study outcome equation (P = 0.031).
TNFR1 is a strong prognostic factor for all-cause mortality in T2D with renal dysfunction, and its clinical utility is suggested in addition to established risk factors for all-cause mortality.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Cause of Death</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - mortality</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - mortality</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Epidemiology</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Glomerular Filtration Rate - physiology</subject><subject>Humans</subject><subject>Kidney diseases</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - etiology</subject><subject>Kidney Failure, Chronic - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Receptors, Tumor Necrosis Factor, Type I - blood</subject><subject>Risk Factors</subject><subject>TNF inhibitors</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0c1qGzEQB3BRGho37aEvUASl0B621deutLmZjZ2EpGlJHHpcxpIWK6wlV9ol-H3yoJWxk0JPEpqfZgb-CH2g5BvjXH43mvKClYq8QhNa87IoS6Feowmhoi7KumbH6G1KD4QQIZR6g46ZqBgnrJqgp2lKQTsYXPA4dPjOxnGNm-C19UN8eV7czG8p_u2GFZ72fdHAmCz-EeIAvRu22Hn8K9v8Je3RYruxmOEzB0s72ITBG9ysYvBO4ytnvN3mWrKQ7Cmeh74Pj8W42Q0aVhbf3d-eXU7PZzezvMgqD3mHjjrok31_OE_Q_Xy2aC6K65_nl830utBcqqGwVElGjOlqYShTckm1JQDMQFcyKTkxHVS1NkorWdVAuKFWgFLQyXyRFT9BX_Z9NzH8GW0a2rVL2vY9eBvG1NKSKkUFlSrTT__RhzBGn7fLilHKRCnrrL7ulY4hpWi7dhPdGuK2paTdRdfuomt30WX78dBxXK6teZHPWWXw-QAgaei7CF679M8pIaqaS_4XoLmfig</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>SAULNIER, Pierre-Jean</creator><creator>GAND, Elise</creator><creator>VELHO, Gilberto</creator><creator>SOSNER, Philippe</creator><creator>ZAOUI, Philippe</creator><creator>HADJADJ, Samy</creator><creator>RAGOT, Stephanie</creator><creator>DUCROCQ, Gregory</creator><creator>HALIMI, Jean-Michel</creator><creator>HULIN-DELMOTTE, Charlotte</creator><creator>LLATY, Pierre</creator><creator>MONTAIGNE, David</creator><creator>RIGALLEAU, Vincent</creator><creator>ROUSSEL, Ronan</creator><general>American Diabetes Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20140501</creationdate><title>Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort</title><author>SAULNIER, Pierre-Jean ; GAND, Elise ; VELHO, Gilberto ; SOSNER, Philippe ; ZAOUI, Philippe ; HADJADJ, Samy ; RAGOT, Stephanie ; DUCROCQ, Gregory ; HALIMI, Jean-Michel ; HULIN-DELMOTTE, Charlotte ; LLATY, Pierre ; MONTAIGNE, David ; RIGALLEAU, Vincent ; ROUSSEL, Ronan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-e18720ddf94d1287b1ce0aa2daf527730dfa69cd8c8769a03d1e4a88af71e4763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Cause of Death</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - mortality</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - mortality</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Epidemiology</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Glomerular Filtration Rate - physiology</topic><topic>Humans</topic><topic>Kidney diseases</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - etiology</topic><topic>Kidney Failure, Chronic - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Receptors, Tumor Necrosis Factor, Type I - blood</topic><topic>Risk Factors</topic><topic>TNF inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SAULNIER, Pierre-Jean</creatorcontrib><creatorcontrib>GAND, Elise</creatorcontrib><creatorcontrib>VELHO, Gilberto</creatorcontrib><creatorcontrib>SOSNER, Philippe</creatorcontrib><creatorcontrib>ZAOUI, Philippe</creatorcontrib><creatorcontrib>HADJADJ, Samy</creatorcontrib><creatorcontrib>RAGOT, Stephanie</creatorcontrib><creatorcontrib>DUCROCQ, Gregory</creatorcontrib><creatorcontrib>HALIMI, Jean-Michel</creatorcontrib><creatorcontrib>HULIN-DELMOTTE, Charlotte</creatorcontrib><creatorcontrib>LLATY, Pierre</creatorcontrib><creatorcontrib>MONTAIGNE, David</creatorcontrib><creatorcontrib>RIGALLEAU, Vincent</creatorcontrib><creatorcontrib>ROUSSEL, Ronan</creatorcontrib><creatorcontrib>SURDIAGENE Study Group</creatorcontrib><creatorcontrib>for the SURDIAGENE Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SAULNIER, Pierre-Jean</au><au>GAND, Elise</au><au>VELHO, Gilberto</au><au>SOSNER, Philippe</au><au>ZAOUI, Philippe</au><au>HADJADJ, Samy</au><au>RAGOT, Stephanie</au><au>DUCROCQ, Gregory</au><au>HALIMI, Jean-Michel</au><au>HULIN-DELMOTTE, Charlotte</au><au>LLATY, Pierre</au><au>MONTAIGNE, David</au><au>RIGALLEAU, Vincent</au><au>ROUSSEL, Ronan</au><aucorp>SURDIAGENE Study Group</aucorp><aucorp>for the SURDIAGENE Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>37</volume><issue>5</issue><spage>1425</spage><epage>1431</epage><pages>1425-1431</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>Renal dysfunction is a key risk factor for all-cause mortality in patients with type 2 diabetes (T2D). Circulating tumor necrosis factor receptor 1 (TNFR1) was recently suggested as a strong biomarker for end-stage renal failure in T2D. However, its relevance regarding all-cause death has yet to be conclusively established. We aimed to assess the prognostic value of serum TNFR1 concentration for all-cause death in T2D and diabetic kidney disease (DKD) from the SURDIAGENE (Survie, Diabete de type 2 et Genetique) study.
A total of 522 T2D patients with DKD (estimated glomerular filtration rate [eGFR] <60 and/or urinary albumin-to-creatinine ratio [uACR] >30 mg/mmol) were followed for a median duration of 48 months, and 196 deaths occurred.
Incidence rate (95% CI) for death increased as quartiles of TNFR1 concentration increased (first quartile: 4.7% patient-years [3.0-6.3%]; second quartile: 7.7% [5.4-10.0%]; third quartile: 9.3% [6.7-11.9%]; fourth quartile: 15.9% [12.2-19.5%]). In multivariate analysis taking age, diabetes duration, HbA1c, uACR, and eGFR into account, compared with the first quartile, patients from the fourth quartile had an adjusted hazard ratio for death of 2.98 (95% CI 1.70-5.23). The integrated discrimination improvement index was statistically significant when adding TNFR1 concentration to the UK Prospective Diabetes Study outcome equation (P = 0.031).
TNFR1 is a strong prognostic factor for all-cause mortality in T2D with renal dysfunction, and its clinical utility is suggested in addition to established risk factors for all-cause mortality.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>24623026</pmid><doi>10.2337/dc13-2580</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2014-05, Vol.37 (5), p.1425-1431 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1518814178 |
| source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Biological and medical sciences Biomarkers Biomarkers - blood Cause of Death Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - mortality Diabetes. Impaired glucose tolerance Diabetic Nephropathies - blood Diabetic Nephropathies - mortality Endocrine pancreas. Apud cells (diseases) Endocrinopathies Epidemiology Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Follow-Up Studies General aspects Glomerular Filtration Rate - physiology Humans Kidney diseases Kidney Failure, Chronic - blood Kidney Failure, Chronic - etiology Kidney Failure, Chronic - mortality Male Medical sciences Metabolic diseases Middle Aged Mortality Prognosis Prospective Studies Public health. Hygiene Public health. Hygiene-occupational medicine Receptors, Tumor Necrosis Factor, Type I - blood Risk Factors TNF inhibitors |
| title | Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A58%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20Serum%20Concentration%20of%20TNFR1%20With%20All-Cause%20Mortality%20in%20Patients%20With%20Type%202%20Diabetes%20and%20Chronic%20Kidney%20Disease:%20Follow-up%20of%20the%20SURDIAGENE%20Cohort&rft.jtitle=Diabetes%20care&rft.au=SAULNIER,%20Pierre-Jean&rft.aucorp=SURDIAGENE%20Study%20Group&rft.date=2014-05-01&rft.volume=37&rft.issue=5&rft.spage=1425&rft.epage=1431&rft.pages=1425-1431&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc13-2580&rft_dat=%3Cproquest_cross%3E1518814178%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1521124579&rft_id=info:pmid/24623026&rfr_iscdi=true |